



Anticancer Drug Discovery Based on Natural Products: From Computational Approaches to Clinical Studies

Guest Editors:

Dr. Rajeev K. Singla

Institutes for Systems Genetics,
Frontiers Science Center for
Disease-Related Molecular
Network, West China Hospital,
Sichuan University, Chengdu
610041, China

Prof. Dr. Anupam Bishayee

College of Osteopathic Medicine,
Lake Erie College of Osteopathic
Medicine, Bradenton, FL 34211,
USA

Deadline for manuscript
submissions:

31 December 2024

Message from the Guest Editors

Translational aspects of preclinical studies to clinical level are of utmost importance for natural products to progress from bench to bedside. In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following:

- Bioactive natural compounds from diverse sources, including plants, animals, microbes, and marine organisms, against various cancers: Computational, preclinical, and clinical studies;
- Mechanism-based anticancer activity of natural compounds (botanical drugs, uncharacterized plant extracts, and fractions are excluded);
- Nanoformulations for site-targeted anticancer drug delivery;
- Cheminformatics and bioinformatics integrating genomic data and computational modeling;
- Role of translational informatics in natural-product-based anticancer drug discovery.

Note:

- Manuscripts describing the effects of botanical or natural drugs/extracts/fractions will not be considered;
- The active ingredients or constituents of the natural agents should be determined or presented;
- The toxicity of the natural compounds should be evaluated in both in vitro and in vivo studies.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)